Navigation Links
Agilux Laboratories Announces the Launch of GLP LC/MS/MS Bioanalytical Services
Date:1/25/2010

Expanded GLP bioanalytical testing services makes Agilux the largest bioanalytical CRO in New England.

Worcester, MA (PRWEB) January 25, 2010 -- Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides bioanalytical and in vitro ADMET services for the biotechnology and pharmaceutical industries, has launched GLP compliant LC/MS/MS bioanalytical services supporting nonclinical and clinical studies.

Founded in 2007, Agilux has grown into the largest bioanalytical contract laboratory in New England by focusing on high quality, rapid turnaround services for discovery support. Agilux can now deliver the same high quality, rapid turnaround services to support GLP compliant nonclinical and clinical studies.

The "green field" start of the GLP LC/MS/MS bioanalytical service has allowed Agilux to incorporate the very latest technology with many novel, innovative approaches. The management team's extensive knowledge and experience in the GLP bioanalytical environment result in novel, efficient processes that are fully compliant with the latest regulations. With renowned customer service, Agilux is focused on delivering "Better Data Faster"

"At Agilux, we have challenged ourselves to innovate to the advantage of our clients. Our highly successful Discovery 2.0 has demonstrated that there was room to innovate in the discovery bioanalytical services space. In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service" said Jim Jersey, president and CEO at Agilux.

About Agilux Laboratories, Inc.

Agilux Laboratories, Inc. is a contract research organization (CRO) focused on bioanalytical and PK/PD testing services for the biotech and pharmaceutical industries. Leveraging industry and contract research experience of its management team, the company delivers high quality bioanlaytical chemistry and PK/PD data more rapidly. Agilux helps clients make better decisions during drug discovery and development by providing quality data earlier in the research process by using technologies and systems that increase turnaround speed well beyond industry standards. Founded in 2007 by industry veterans Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in Worcester, MA, and is funded by private equity firm Ampersand Ventures. For more information, call 508-753-5000. Online at www.agiluxlabs.com.

Contact:
Steve Guyan
Vice President, Sales and Marketing
(508)-762-4402

# # #

Read the full story at http://www.prweb.com/releases/GLPBioanalytical/AgiluxLabs/prweb3495654.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
2. Underwriters Laboratories Announces Alternative Certification Program for Lead Free Verification of Cooking and Plumbing Products
3. Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry
4. Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
5. Renewal Laboratories(TM) Announces the First Omega3 Supplement Water for Cardiac Health
6. Reportlinker Adds Whos Doing What in Molecular Diagnostics? - Kalorama / Emmes Survey of US Laboratories Report
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
9. ARUP Laboratories Scientist Tanya Sandrock Receives NIH Grant to Search for Additional HIV Therapies
10. Care-Tech Laboratories Agrees to Stop Making, Selling and Distributing Unapproved Antimicrobial Products
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at Moffitt ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in an ... and sleep monitoring solutions for the global scientific community. The company’s new CentrePoint ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a ... Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: